×

SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer

SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive Vice President and Chief Financial Officer. In this capacity, Mr. Nassif will oversee the financial, SEC reporting, accounting, legal, investor relations and administrative functions of the company. He had been the company's Chief Financial Officer on a part-time consulting basis since March 2013.

"I am extremely pleased to announce David's appointment as Chief Financial Officer," said Jonathan M. N. Rigby, President and CEO of SteadyMed. "He is an accomplished executive with significant operational and financial expertise in both the public and private sector. David was instrumental in the success of our recent initial public offering and I have no doubt he will be an exceptional asset for our team as we continue to execute our corporate goals."

Mr. Nassif was more recently the President and Chief Financial Officer of Histogen, Inc., a privately-held, regenerative medicine company as well as the Chief Financial Officer of Zogenix, Inc., a publicly-held, specialty pharmaceutical company. Formerly he was the Chief Financial Officer and Senior Vice President of Global Licensing at Amphastar, where he orchestrated several business development transactions. Earlier in his career, Mr. Nassif was the Chief Financial Officer of Cypros Pharmaceutical Corporation where he was responsible for its merger with Ribogene to form Questcor Pharmaceuticals. Mr. Nassif received a B.Sc. in Finance and Management Information Systems from the University of Virginia, with honors, and a J.D. from the University of Virginia School of Law.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead candidate is TrevyentTM, a development stage drug product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the Company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on March 19, 2015. The Company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com Robert H. Uhl Managing Director Westwicke Partners 858-356-5932 robert.uhl@westwicke.comSource: SteadyMed Therapeutics